2Forest Laboratories.Forest Announces FDA Approval of Teflaro(TM)(ceftaroline fosamil)for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.2010-10-29[October 30,2010]. 被引量：1
3Forest Laboratories,Inc.Forest Laboratories presents a-nalysis of two positive pivotal Phase III studies of ceftaro-line for the treatment of community-acquired pneumonia(CAP)at ICAAC[EB/OL].(2009-09-12). 被引量：1
4Ishikawa T,Matsunage N,et al.TAK-599,a Novel N-Phosphono Type Prodrug of Anti-MRSA CephalosporinT - 91825:Synthesis,Physicochemical and Pharmacologi-cal Properties[J].Bioorganic & Medicinal Chemistry 11(2003)2427-2437. 被引量：1
9IshikawaT,Matsunage N,et al.TAK-599,a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825:synthesis,physicochemical and pharmacological properties[J].Bioorg Med Chem,2003.11(11):2427-37. 被引量：1
10Moisan H,Pruneau M,Malouin F.Binding of ceftarolineto penicillin-binding proteins of Staphylococcus aureusand Streptococcus pneumonia[J].J.Antimicrob.Che-mother,2010.65(4). 被引量：1
3CUI LZ,LIAN JQ,Hirarnatsu K,et al.DNA microarray-based identification of genes associated with glycopeptides resistance in Staphylococcus aureus[J].Antimicrob Agents Chemother,2005,49(8):3404-3413. 被引量：1
4Sakoulas G,Eliopoulos GM,Moellefing RC,et al.Staphylococcus aureus aCcessory gene regulator(agr)group Ⅱ:is there a relationship to the development of intermediate level glycopeptide resistance?[J].Infect Dis,2003,187:929. 被引量：1
5Vavra SB,Shaohui Y,Challapalli M,et al.Transcriptional induction of the penicillin-banding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin[J].Antimicrob Agents Chemother,2003,47(3):1028. 被引量：1
6Schaaff F,Reipert A,et al.An elevated mutation frequency favors development of vaneomyein resistance in Staphylococcus aureus[J].Antimicrob Agents Chemother,2002,46(11):3540. 被引量：1
7Yanagihara K,Kohno S.Linezolid versus vancomycin for the treatment of infections caused by Methicillin-resistant Staphylococcus aureus in Japan[J]Mntimicrob Chemother,2007,60(6):1361-1369. 被引量：1
8Brown J.Combining quinupristin/dalfopristin with other agents for resistant infeetions[J].Annals Pharmacotherapy,2004,38(4):677-685. 被引量：1
9Fox PM,Lampen RJ,Stumpf KS,et al.Successful therapy of experimental endocarditic caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and β-lactam antibiotics[J].A ntimicrob Agents Chemother,2006,50(9):2951-2956. 被引量：1
10Yanagihara K,Ohnishic Y.Efficacy of ME1036 against methicillin-resistant Staphylococcus aureus and vancomycin insensitive S.aureus in a model of hematogenous pulmonary infection[J].Inter J Antimicrob Agents,2008,32:401-404. 被引量：1
